Duncker Streett & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Duncker Streett & Co’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-300	Closed	-$39K	–	543
2019 Q2	$39K	Buy	+300	New	+$38.7K	0.01%	388
2015 Q3	–	Sell	-200	Closed	-$36K	–	641
2015 Q2	$36K	Hold	200	–	–	0.01%	411
2015 Q1	$35K	Hold	200	–	–	0.01%	424
2014 Q4	$37K	Buy	+200	New	+$37.1K	0.01%	413

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Duncker Streett & Co's ALXN Position: Q3 2019 in Review

Duncker Streett & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 300 shares — an estimated $39K sold.

Duncker Streett & Co first reported a position in ALXN in Q4 2014 and held it in 4 quarters. The position peaked at $39K in Q2 2019. 646 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

Duncker Streett & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Duncker Streett & Co sold 300 Alexion Pharmaceuticals shares in Q3 2019, an estimated $39K.
Duncker Streett & Co first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 4 quarters.
Duncker Streett & Co's Alexion Pharmaceuticals position peaked at $39K in Q2 2019.
646 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Duncker Streett & Co's 13F filing for Q3 2019, filed 31 Oct 2019.